Reimbursing Injections For Retinal Disease

Corcoran, Kevin
March 2005
Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p25
Trade Publication
Presents answers to queries related to Medicare reimbursement for retinal disease in the United States. Status of Medicare reimbursement for intravitreal injections for retinal disease; Implication of the separate procedure status in the code's definition; Effect of place of service on reimbursement.


Related Articles

  • Test Your M0110 -- Episode Timing Skills With These Scenarios.  // Eli's OASIS Alert;Sep2012, Vol. 13 Issue 9, p100 

    The article presents questions and answers related to Outcome & Assessment Information Set (OASIS) item M0110 including the payment episode of the agency whether early or later, representing distinct episodes for answering M0110, and the adjustment made by Medicare to correct the response.

  • Medicare Billing Modifiers. Miller, Ritch; McClelland, Susan; Mulligan, Jaime // ACA News (American Chiropractic Association);Jun2009, Vol. 5 Issue 6, p18 

    The article offers information regarding the usage of Medicare modifiers and its regulations in the U.S. It states that the only service covered for doctors of chiropractic under Medicare is the spine's manual manipulation to correct subluxation. It notes that Medicare does not reimburse for...

  • The Medicare Shuffle: How Many More Verses? Glenn, Chris // Review of Ophthalmology;Aug2008 Part 1 of 2, Vol. 15 Issue 8, p19 

    The author reflects on the issue about the proposed cuts in Medicare physician reimbursement in the U.S. He comments about the private Medicare advantage program which faces the loss of support that was really intended temporarily right from the start. The author says that there is no simple...

  • Now Available: Specific Codes for Smoking Cessation.  // Getting Paid in Behavioral Healthcare;Oct2007, Vol. 12 Issue 10, p1 

    The article offers information on the new generic counseling and/or risk factor reduction intervention codes or health and behavior assessment/intervention codes for smoking cessation programs in the U.S. The new codes will be time-based, G0375 and G0376 codes, which Medicare limits to patients...

  • Medicare: Identifying Third-Party Billing Companies Submitting Claims: HEHS-99-127R.  // GAO Reports;6/2/1999, p1 

    Pursuant to a congressional request, GAO described how the Health Care Financing Administration (HCFA) and its contractors monitor third-party billing companies' involvement in the submission of claims to Medicare. GAO noted that: (1) providers are ultimately responsible for the claims that they...

  • Pareto Rate Setting Strategies: an Application to Medicaid Drug Reimbursement. Morey, Richard C.; David, Robert S.; Dittman, A. // Policy Sciences;Sep1985, Vol. 18 Issue 2, p169 

    The major problem in reimbursement rate setting has, been to develop approaches capable of identifying the inefficient deliverers of service, while recognizing legitimate differences in environmental factors and service orientation. This article suggests several new analytical approaches, based...

  • Lawmakers try new tack to fix physician Medicare payments.  // Contemporary OB/GYN;Aug2002, Vol. 47 Issue 8, p15 

    Focuses on the initiatives of federal lawmakers to modify Medicare payment rates to physicians in the U.S. Estimated revenue of physicians over 10 years if Medicare payment rates are reduced; Obstacles to the proposed Medicare payment changes.

  • Bustin' a CAP. Rubinstein, Elan; Galardi, David // Pharmaceutical Executive;Nov2005, Vol. 25 Issue 11, p85 

    Talks about the efforts of the new Competitive Acquisition Program (CAP) for Medicare Part B drugs to align market forces with the distribution of drugs and biologics that administer in their offices in the U.S. Benefits of the CAP for the Centers for Medicare and Medicaid Services ; Potential...

  • Medications loom large in reimbursement picture. Freeman, L. Neal // Ophthalmology Times;9/15/2007, Vol. 32 Issue 18, p62 

    The article focuses on the issues concerning the Medicare in the U.S. According to the author, many physician-administered drugs are covered for payment except those certain off-label or experimental drugs and those that have already been factored into the fee schedule amount. Meanwhile, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics